Related references
Note: Only part of the references are listed.Peroxisome proliferators-activated receptor γ2 Pro12Ala variant is associated with body mass index in non-alcoholic fatty liver disease patients
A. C. Gupta et al.
HEPATOLOGY INTERNATIONAL (2011)
Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study
Paola Dongiovanni et al.
BMC GASTROENTEROLOGY (2010)
Homozygosity for the Patatin-Like Phospholipase-3/Adiponutrin I148M Polymorphism Influences Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
Luca Valenti et al.
HEPATOLOGY (2010)
Pathology of nonalcoholic fatty liver disease
Elizabeth M. Brunt
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis.
Arun J. Sanyal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ2 in patients with fatty liver diseases
Johannes W. Rey et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2010)
A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans
A. Kotronen et al.
DIABETOLOGIA (2009)
A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity
Silvia Sookoian et al.
JOURNAL OF LIPID RESEARCH (2009)
PPARγ activation in adipocytes is sufficient for systemic insulin sensitization
Shigeki Sugii et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Association between PPARGCIA polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)
Masato Yoneda et al.
BMC GASTROENTEROLOGY (2008)
The Kruppel-Like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease
Luca Miele et al.
GASTROENTEROLOGY (2008)
Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease
Stefano Romeo et al.
NATURE GENETICS (2008)
Interaction between PPARγ2 variants and gender on the modulation of body weight
Eleonora Morini et al.
OBESITY (2008)
Abnormalities of Lipid Metabolism in Nonalcoholic Fatty Liver Disease
Onpan Cheung et al.
SEMINARS IN LIVER DISEASE (2008)
The Epidemiology of Nonalcoholic Fatty Liver Disease: A Global Perspective
Mariana Lazo et al.
SEMINARS IN LIVER DISEASE (2008)
Mechanisms of Disease Progression in Nonalcoholic Fatty Liver Disease
Janice Jou et al.
SEMINARS IN LIVER DISEASE (2008)
Effect of peroxisome proliferator-activated receptors-γ and co-activator-1α genetic polymorphisms on plasma adiponectin levels and susceptibility of non-alcoholic fatty liver disease in Chinese people
Yang Hui et al.
LIVER INTERNATIONAL (2008)
Polymorphism in microsomal triglyceride transfer protein: A link between liver disease and atherogenic postprandial lipid profile in NASH?
Roberto Gambino et al.
HEPATOLOGY (2007)
Review:: Peroxisome proliferator-activated receptor γ and adipose tissue -: Understanding obesity-related changes in regulation of lipid and glucose metabolism
Arya M. Sharma et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Renata Belfort et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Mattias Ekstedt et al.
HEPATOLOGY (2006)
Design and validation of a histological scoring system for nonalcoholic fatty liver disease
DE Kleiner et al.
HEPATOLOGY (2005)
Association of the Pro12Ala and C1431T variants of PPARG and their haplotypes with susceptibility to Type 2 diabetes
ASF Doney et al.
DIABETOLOGIA (2004)
DNA extraction from archival formalin-fixed, paraffin-embedded tissues: heat-induced retrieval in alkaline solution
SR Shi et al.
HISTOCHEMISTRY AND CELL BIOLOGY (2004)
Molecular mediators of hepatic steatosis and liver injury
JD Browning et al.
JOURNAL OF CLINICAL INVESTIGATION (2004)
A Pilot Study of Vitamin E Versus Vitamin E and Pioglitazone for the Treatment of Nonalcoholic Steatohepatitis
Arun J. Sanyal et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2004)
A pilot study of ploglitazone treatment for nonalcoholic steatohepatitis
K Promrat et al.
HEPATOLOGY (2004)
Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis
C Namikawa et al.
JOURNAL OF HEPATOLOGY (2004)
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone
BA Neuschwander-Tetri et al.
HEPATOLOGY (2003)
Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C
JM Hui et al.
HEPATOLOGY (2003)
Haplotype analysis of the PPARγ Pro12Ala and C1431T variants reveals opposing associations with body weight -: art. no. 21
A Doney et al.
BMC GENETICS (2002)
Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease
L Valenti et al.
GASTROENTEROLOGY (2002)
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
D Altshuler et al.
NATURE GENETICS (2000)
Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with Type II diabetes
S Bernard et al.
DIABETOLOGIA (2000)
Share Paper
